Expansion Therapeutics, Inc., a Boston, MA-based biotechnology company focused on developing transformative oral medicines for severe RNA-mediated diseases, closed an $80m Series B financing.
The round was led by Cormorant Asset Management with participation from new investors Westlake Village BioPartners, Surveyor Capital (a Citadel company) and Logos Capital as well as Series A investors RA Capital Management, 5AM Ventures, Kleiner Perkins, Sanofi Ventures and Novartis Venture Fund.
Proceeds from the financing will be used to advance the company’s small molecule RNA platform (SMiRNA™) to identify clinical candidates in myotonic dystrophy type 1 (DM1), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and various tauopathies.
Led by Renato Skerlj, Ph.D., President and Chief Executive Officer, Expansion Therapeutics is a biotechnology company focused on developing oral medicines for severe RNA-mediated diseases including neurodegenerative disorders. Based on exclusive worldwide rights to research from the laboratory of Matthew D. Disney, Ph.D., at Scripps Research, Expansion has assembled the intellectual property, know-how, and proprietary enabling technologies and tools necessary to facilitate the creation of potent and specific small molecule RNA modulators. Through this platform, Expansion is building a portfolio of novel RNA-targeted drug candidates with activity across a broad number of severe RNA-mediated disease indications.
The company’s research facility is located in Jupiter, Florida.